UPB insider transaction filings
Upstream Bio, Inc. — 32 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-17. Screen UPB transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-17 | 4 | Houghton Adam — Chief Business Officer | Sale (S): 700 @ $6.10 | EDGAR |
| 2026-06-17 | 4 | Deykin Aaron — Chief Medical Officer | Sale (S): 895 @ $6.10 | EDGAR |
| 2026-06-17 | 4 | Ambrose Allison — General Counsel | Sale (S): 477 @ $6.10 | EDGAR |
| 2026-06-17 | 4 | Sutherland Everett Rand — Chief Executive Officer, Director | Sale (S): 2,095 @ $6.10 | EDGAR |
| 2026-06-17 | 4 | GRAY MICHAEL — CFO and COO | Sale (S): 853 @ $6.10 | EDGAR |
| 2026-06-11 | 4 | Ruddy Marcella K. — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Fleming Harold Edward — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Chimovits Erez — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Ratcliffe Liam — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Beckman Daniella — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Renaud Ronald C JR — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Deykin Aaron — Chief Medical Officer | Sale (S): 894 @ $9.29 | EDGAR |
| 2026-03-17 | 4 | Ambrose Allison — General Counsel | Sale (S): 475 @ $9.29 | EDGAR |
| 2026-03-17 | 4 | Houghton Adam — Chief Business Officer | Sale (S): 699 @ $9.29 | EDGAR |
| 2026-03-17 | 4 | Sutherland Everett Rand — Chief Executive Officer, Director | Sale (S): 2,093 @ $9.29 | EDGAR |
| 2026-03-17 | 4 | GRAY MICHAEL — CFO and COO | Sale (S): 852 @ $9.29 | EDGAR |
| 2026-01-06 | 4 | Deykin Aaron — Chief Medical Officer | Grant/award (A): 32,000 @ $0 · Grant/award (A): 96,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Ambrose Allison — General Counsel | Grant/award (A): 17,000 @ $0 · Grant/award (A): 51,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Houghton Adam — Chief Business Officer | Grant/award (A): 25,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Sutherland Everett Rand — Chief Executive Officer, Director | Grant/award (A): 75,000 @ $0 · Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | GRAY MICHAEL — CFO and COO | Grant/award (A): 30,500 @ $0 · Grant/award (A): 91,500 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Ruddy Marcella K. — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Fleming Harold Edward — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Chimovits Erez — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Ratcliffe Liam — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Beckman Daniella — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Renaud Ronald C JR — Director | Grant/award (A): 17,096 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Houghton Adam — Chief Business Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Deykin Aaron — Chief Medical Officer | Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Ambrose Allison — General Counsel | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Sutherland Everett Rand — Chief Executive Officer, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | GRAY MICHAEL — CFO and COO | Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Upstream Bio, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-11 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-11 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-02 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=UPB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →